Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy
NL-OMON56426Phase 3Recruiting
- Sponsor
- MyoKardia
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Mavacamten with Placebo (2 arms). Primary endpoints: Change from baseline in KCCQ-23 CSS at Week 48 and Change from baseline in pVO2 at Week 48. Started Aug 2023; status: recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON56426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56426.